• Publications
  • Influence
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
TLDR
The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome. Expand
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
TLDR
PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC, providing preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study. Expand
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
TLDR
There was a significant dose-dependent increase in risk of proteinuria and hypertension in patients with cancer who received bevacizumab. Expand
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
TLDR
This vaccine regimen can be safely given in patients undergoing radiation therapy for localized prostate cancer, with the majority of patients generating a PSA-specific cellular immune response to vaccine. Expand
Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer
TLDR
The common SLCO1B3 GG/AA haplotype is associated with impaired testosterone transport and improved survival in patients with prostatic cancer. Expand
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
TLDR
The addition of bevacizumab and thalidomide to docetaxel is a highly active combination with manageable toxicities, and the estimated median survival is encouraging, given the generally poor prognosis of this patient population. Expand
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
TLDR
Evidence is provided that patients with more indolent mCRPC (Halabi predicted survival ≥18 months) may best benefit from vaccine therapy, and treg suppressive function was shown to decrease following vaccine in patients surviving longer than predicted, and increase in patients survive less than predicted. Expand
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
TLDR
A one compartment model with four transit absorption compartments and enterohepatic circulation (EHC) adequately described sorafenib disposition and can be used to simulate and explore alternative dosing regimens and to develop exposure-response relationships for sorafanib. Expand
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
TLDR
This pilot study indicates that genotype status of UGT1A1, U GT1A9, and ABCC2 and serum bilirubin concentration increases reflect abnormally high AUC in patients treated with sorafenib. Expand
Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents
TLDR
It is suggested that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid in chemotherapy-naïve men with metastatic castration resistant prostate cancer. Expand
...
1
2
3
4
5
...